Want to see HLN full AI Analyst Report?
Top Page
Haleon PLC Sponsored ADR
(NYSE:HLN)
Select Model
Select Model
Rating:66Neutral
Price Target:
$10.00
▲(5.04% Upside)
Action:Reiterated
Date:02/27/26
The score is driven primarily by improving profitability and solid cash-flow quality, supported by constructive (but not strong) technical signals. It is held back by soft recent revenue/volume trends and a moderate-to-rich valuation (P/E ~25.5) with only a modest dividend yield, while the earnings call reinforced steady 2026 growth guidance alongside ongoing near-term category and U.S. headwinds.
Positive Factors
Oral-health brand leadership
Haleon’s leading oral-health franchises, led by Sensodyne, deliver sustained high-single to double-digit growth. Strong brand equity drives retailer placement, pricing resilience and higher-margin mix, supporting predictable revenue and durable cash conversion over the medium term.
Negative Factors
Weak volume and top-line
Persistent low volume growth (≈1% avg over three years) versus a 2%+ internal target limits sustainable top-line expansion. Even with margin gain, weak unit growth can cap long-term revenue power, increase reliance on pricing/A&P, and pressure market share versus faster-growing peers.
Read all positive and negative factors
Positive Factors
Negative Factors
Oral-health brand leadership
Haleon’s leading oral-health franchises, led by Sensodyne, deliver sustained high-single to double-digit growth. Strong brand equity drives retailer placement, pricing resilience and higher-margin mix, supporting predictable revenue and durable cash conversion over the medium term.
Read all positive factors
Haleon PLC Sponsored ADR Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which may need strategic adjustments.
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyHaleon PLC Sponsored ADR (HLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.99B
Dividend Yield1.74%
Average Volume (3M)10.28M
Price to Earnings (P/E)29.1
Beta (1Y)0.11
Revenue Growth1.30%
EPS Growth21.31%
CountryUS
Employees24,561
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.37
Shares Outstanding4,415,081,000
10 Day Avg. Volume12,002,400
30 Day Avg. Volume10,284,714
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio17.06
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.35
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda13.02
Forecast
1Y Price Target
$11.00Price Target Upside15.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.55
Revenue Forecast (FY)$15.25B
Haleon PLC Sponsored ADR Business Overview & Revenue Model
Company Description
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extend...
How the Company Makes Money
Haleon makes money primarily by manufacturing, marketing, and selling branded consumer health products. Revenue is generated from product sales across major categories: (1) Oral Health (e.g., Sensodyne, Parodontax, Polident), (2) Pain Relief (e.g....
Haleon PLC Sponsored ADR Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call balances clear operational and strategic progress (notably strong margin/cost improvements, Oral Health outperformance, emerging markets growth, increased A&P/R&D investment, and a planned $175–$200M cost saving reorganization) against meaningful top-line and volume challenges (soft U.S. market, cold & flu season weakness, category-specific headwinds, and regional retailer/inventory issues). Management presented realistic 2026 guidance (3%–5%) while reiterating confidence in returning to the 4%–6% medium-term ambition as U.S. performance, distribution gains, and productivity benefits materialize.Positive Updates
Organic Sales Growth (FY2025) and 2026 Guidance
FY2025 organic sales growth of 3%. Guidance for FY2026 set at 3%–5%, with management reiterating a medium-term ambition of 4%–6%.
Negative Updates
Top-Line Disappointment and Volume Weakness
Top-line underperformance in FY2025 (3% organic) and historically low volume performance (average volume ~1% over past 3 years), below peer best-in-class volume levels (target ~2%+). Company acknowledges volume is a key focus for 2026.
Read all updates
Q4-2025 Updates
Positive
Negative
Organic Sales Growth (FY2025) and 2026 Guidance
FY2025 organic sales growth of 3%. Guidance for FY2026 set at 3%–5%, with management reiterating a medium-term ambition of 4%–6%.
Read all positive updates
Company Guidance
Management reiterated FY2026 organic sales guidance of 3–5% (with a medium‑term ambition of 4–6%), noting 2025 organic growth was 3% (U.S. down ~0.5%, LatAm mid‑single digits) and that Q1 cold & flu will be below last year; they expect the U.S. to return to growth in 2026 and cited confirmed Q2 shelving/reset wins. Key financial/efficiency metrics: gross margin improved 220 basis points in 2025, supply‑chain productivity guidance of 50–80 bps pa going forward, and expected high‑single‑digit operating growth at constant currency funded by $175–200m of gross savings from the reorganisation. Marketing and innovation: A&P up ~7.5% (to ~20.5% of sales) and R&D up ~7.7%, with roughly half incremental A&P to Oral Health and half to emerging markets; working media +12%, ROI up mid‑single digits, digital ~60% of working media. Other metrics called out include 70% of cold & flu sales outside the U.S., 60% of the business gaining/maintaining share, 80% of Asia‑Pac growth from volume, India double‑digit growth, China mid‑single digits with e‑commerce ~40% of sales and Douyin >100% growth, and 18 brands making 90% of Amazon sales (16 of 18 higher share online than offline).Haleon PLC Sponsored ADR Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
63
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.03B | 11.23B | 11.30B | 10.86B | 9.54B |
| Gross Profit | 6.99B | 6.95B | 6.96B | 6.58B | 5.95B |
| EBITDA | 2.88B | 2.51B | 2.35B | 2.18B | 2.21B |
| Net Income | 1.63B | 1.44B | 1.05B | 1.06B | 1.39B |
Balance Sheet | |||||
| Total Assets | 32.57B | 34.31B | 34.05B | 34.81B | 34.45B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 2.25B | 1.04B | 684.00M | 414.00M |
| Total Debt | 8.59B | 10.10B | 9.46B | 10.44B | 991.00M |
| Total Liabilities | 16.12B | 18.09B | 17.33B | 18.36B | 7.97B |
| Stockholders Equity | 16.40B | 16.17B | 16.61B | 16.33B | 26.36B |
Cash Flow | |||||
| Free Cash Flow | 1.97B | 2.05B | 1.76B | 1.74B | 1.06B |
| Operating Cash Flow | 2.29B | 2.30B | 2.10B | 2.06B | 1.36B |
| Investing Cash Flow | -567.29M | 528.00M | -134.00M | -8.78B | -33.00M |
| Financing Cash Flow | -2.55B | -1.54B | -1.57B | 6.91B | -1.24B |
Haleon PLC Sponsored ADR Technical Analysis
Positive
9.52
Price Trends
9.17
Positive
9.71
Negative
9.60
Negative
Market Momentum
-0.01
Negative
54.49
Neutral
85.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLN, the sentiment is Positive. The current price of 9.52 is above the 20-day moving average (MA) of 9.04, above the 50-day MA of 9.17, and below the 200-day MA of 9.60, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.49 is Neutral, neither overbought nor oversold. The STOCH value of 85.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HLN.
Haleon PLC Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $11.95B | 26.39 | 11.76% | 0.64% | -1.06% | -26.71% | |
66 Neutral | $38.99B | 29.15 | 6.43% | 1.74% | 1.30% | 21.31% | |
62 Neutral | $48.49B | 40.30 | 2.61% | 3.86% | -0.47% | -225.21% | |
61 Neutral | $38.44B | 23.93 | 20.79% | ― | 5.76% | ― | |
56 Neutral | $18.64B | -60.55 | -1.97% | 3.99% | 2.14% | 91.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.44B | -0.81 | -50.65% | 8.48% | -3.62% | -932.84% |
* Healthcare Sector Average
HLN
Haleon PLC Sponsored ADR
9.33
-0.83
-8.19%
RDY
Dr Reddy's Laboratories
14.49
-0.38
-2.52%
VTRS
Viatris
15.88
7.05
79.82%
PRGO
Perrigo Company
10.39
-14.88
-58.88%
TEVA
Teva Pharmaceutical
33.88
17.24
103.61%
TAK
Takeda Pharmaceutical Company
16.03
0.66
4.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.